AI-generated analysis. Always verify with the original filing.
On March 27, 2026, the Majority Stockholder of FOXO Technologies Inc. — Rennova Health, Inc., controlled by the Company’s CEO — approved by written consent an amendment to increase the authorized Class A Common Stock from 10,000,000,000 to 25,000,000,000 shares, effective 20 days after mailing of the definitive Schedule 14C Information Statement.
This filing reflects a highly consequential corporate governance event: a near-total concentration of voting control enables the CEO-controlled Rennova Health, Inc. to unilaterally approve a 150% expansion of FOXO’s authorized common stock without minority shareholder input or a formal vote. The action — increasing authorized shares from 10 billion to 25 billion — materially alters the Company’s capital structure and creates significant future flexibility for equity issuances, including potential financings, acquisitions, employee compensation, or strategic partnerships. While no immediate issuance is disclosed, the amendment removes a statutory cap that could otherwise constrain such activities. The timing and mechanics — use of written consent, March 20, 2026 record date, April 1 PRE 14C filing, and 20-day post-mailing effectiveness — indicate a deliberate, procedurally compliant execution under Delaware law. For investors, this underscores both the extreme control dynamic at FOXO and the heightened risk of dilution or strategic shifts driven solely by the controlling shareholder, with no requirement for independent board recommendation or minority approval. The absence of any stated purpose, use of proceeds, or conditions further amplifies uncertainty regarding how and when the additional shares may be deployed.